BridgeBio Pharma director Andrea Ellis executed a share sale on March 4, 2026, disposing of 64,921 shares of common stock for a total of $4,211,301. The sale was transacted at a weighted average price of $64.8681 per share, with individual trade prices spanning from $64.255 up to $65.21.
On the same day as the sale, Ellis exercised stock options that enabled the acquisition of 64,921 shares of BridgeBio common stock at an exercise price of $8.45 per share, representing a cash outlay of $548,582. According to corporate filings, the disposition was carried out under a pre-arranged Rule 10b5-1 trading plan that Ellis adopted on December 3, 2025. After these transactions, Ellis directly holds 18,589 shares of the company.
Market performance details included in the filing show BridgeBio shares have gained 105 percent over the last 12 months and were trading at $65.36 at the time of reporting, implying a market capitalization of $12.73 billion.
Separately, BridgeBio reported fourth-quarter revenue of $154.2 million, topping analyst expectations of $146.16 million. The company attributed the revenue increase primarily to $146.0 million in net product revenue from Attruby, its treatment for transthyretin amyloid cardiomyopathy.
Despite the top-line beat, BridgeBio posted an adjusted loss of $1.00 per share for the quarter, wider than the consensus estimate of a $0.72 loss. The company also disclosed a clinical update: interim data from the Phase 3 FORTIFY trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 met the trial's efficacy endpoints. BridgeBio said it will present the interim analysis on March 11 at the MDA Clinical and Scientific Conference in Orlando, Florida.
Analysis referenced in the filing cites InvestingPro, which assesses the stock as undervalued relative to its Fair Value and lists the company among the Most Undervalued cohort. The filing notes that investors may consult a Pro Research Report for a more detailed examination of valuation metrics.
The sequence of transactions by a director combined with concurrent option exercises, the company earnings beat on revenue, the larger-than-expected adjusted loss, and the positive interim clinical readout are the principal elements disclosed in the filings and corporate announcements.